Showing posts with label HCC. Show all posts
Showing posts with label HCC. Show all posts

Wednesday, 13 December 2023

Evaluation of In-vitro Cytotoxicity Activity of Costus igneus (Insulin Plant) and the Potential Role of its Phytochemical Constituents in Hepatocellular Carcinoma | Chapter 7 | Advanced Concepts in Pharmaceutical Research Vol. 3

 Costus igneus and allure secondary metabolites have happened widely evaluated and used to treat subjects with diabetes with metabolic condition. Recent evidence submitted that non-alcoholic fatty liver affliction (NAFLD) and diabetes associated metabolic condition were the important risk factors for hepatocellular abnormal growth in animate being (HCC). So, herbals with insulin sensitizing characteristics have a promising duty in the control of metabolic syndrome and tumor. This study was conducted to evaluate the artificial anticancer activity of the ethanolic extract of Costus igneus leaves against hepatocellular abnormal growth in animate being (HepG2) cells. Artificial cytotoxicity activity (MTT assay) of the plant extract leaves was acted with eight different concentrations (1000 to7.8µg/ml) and the allotment of viability was premeditated from the graph. The aggregation required for a 50% being inhibition (IC 50) was calculated as 62.5µg/ml. Still, 74.57% and 22.65% of cell animation were produced apiece concentration of 7.8µg/ml and 1000µg/ml individually. These results observed the cytotoxic activity of ethanolic extract of Costus igneus leaves and confirmed the potential role of Costus igneus phytochemical possessions against hepatocellular carcinoma.

Author(s) Details:

Glory Josephine I.,
Department of Pharmacology, Sree Balaji Medical College & Hospital, Bharath Institute of Higher Education and Research (BIHER), Chennai 600044, India.

Please see the link here: https://stm.bookpi.org/ACPR-V3/article/view/12700

Friday, 13 January 2023

Advances in Treating Chronic Disease| Book Publisher International

 Since ancient times, in the medical field, people have taken advantage of natural substances to cure diseases. Today, modern medicine is constantly developing, inheriting from the ancients to continue to conduct new research and produce effective treatment products for several diseases that are considered chronic today.

The compositions mentioned in the book have successfully treated a number of supposedly chronic diseases, such as cirrhosis and hepatocellular carcinoma caused by HBV and HCV infections; increased antibodies against COVID-19 in immunocompromised patients, infertility due to orchitis, the testicles are unable to produce spermatozoon, help the testicles complete five successive stages: (1) spermatogonia, (2) primary spermatocytes, (3) secondary spermatocytes, (4) spermatids, and (5) spermatozoon; protecting the fetus, and helping the fetus to develop to full term in a uterus with multiple fibroids. The selective compositions act on the patient's immune system, helping the body to resist harmful effects from the environment. Thanks to the natural substances: Flavonoids; Ascorbic Acid; Pyridoxal phosphate; Pregnenolone, they act as anti-inflammatory agents, enzymes that catalyze the body's chain reactions, as well as natural hormones. They have corrected chronic inflammatory disorders, tumors that grow out of control, causing a number of dangers to the patient's health. Research has shown that flavonoids and vitamins such as Ascorbic Acid, Pyridoxal phosphate, and Pregnenolone mentioned in this book have the necessary biological activity. They have a high impact potential, help the body to regulate, inactivate viruses, dissolve inflammatory tissue, prevent and destroy cancer cells at an early stage.

With practical evidence, the book will give readers an overview of the potential that needs to be discovered from nature to serve human life.

Author(s) Details:

Nguyen Thi Trieu,
Clinical Drug Research and Development Department under Saigon Biopharma Company, Vietnam.

Tran Minh Duc,
Clinical Drug Research and Development Department under Saigon Biopharma Company, Vietnam.

Tran Minh Cam Tu,
Clinical Drug Research and Development Department under Saigon Biopharma Company, Vietnam.

Please see the link here: https://stm.bookpi.org/ATCD/article/view/8972

Tuesday, 10 August 2021

Factors Affecting Outcomes in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization: A Retrospective Analysis | Chapter 14 | Highlights on Medicine and Medical Science Vol. 15

 Patients with hepatocellular carcinoma (HCC) have a wide range of results after transarterial chemoembolization (TACE).

The purpose of this study is to determine which factors influence the result of TACE for HCC.

Methods: We used Fisher's exact test and Mann Whitney U test for univariate analysis and the Kaplan-Meier technique and Cox proportional hazard models to assess survival in HCC patients treated with TACE at the VA Medical Center in Gainesville, Florida, from January 2001 to December 2010.

Results: A total of 82 patients were enrolled in the study, 45 of whom received doxorubicin drug eluting beads (DEB TACE) and 37 of whom received conventional (CON) TACE. With the exception of the CON TACE's higher MELD score, the two TACE groups shared identical features. Survival was linked with TACE type (p= 0.022), Child-Pugh (CP) class (p= 0.038), MELD score (p= 0.028), AFPmax (p=0.0002), and response after first TACE (p= 0.006) in univariate analysis. The DEB TACE group had a substantial survival benefit (p=0.014) over the CON TACE group (-26.4 months versus 15.8 months, respectively) and in patients with lower MELD levels (p=0.005), according to Kaplan Meier analysis. A multivariable analysis found a statistically significant interaction between TACE type and MELD score (p=0.395), with DEB TACE patients outliving CON TACE patients, but the effect lessening as MELD levels climbed. Furthermore, AFPmax significantly increased the chance of death (hazard ratio 1.15, 95 percent CI= [1.06, 1.26], p=0.0001).

Conclusions: In CP class A, survival following TACE for HCC is improved after DEB TACE, with a lower MELD score and AFPmax.

Author (s) Details

Amitabh Suman
University of Florida, Gainesville and VA Medical Center, Gainesville, Florida, United States.

View Book :- https://stm.bookpi.org/HMMS-V15/article/view/2475